-

ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)

VICTORIA, British Columbia--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference being held virtually on September 13-15, 2021.

Jennifer Bath, CEO of ImmunoPrecise, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event: H.C. Wainwright 23rd Annual Global Investment Conference (Virtual Conference)

Date: September 13-15, 2021

Presentation Day & Time: September 10, 6:00 PM (EDT)

Location: https://journey.ct.events/view/8a904567-5abc-4305-b0af-d61d08691320

H.C. Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For further information, visit www.immunoprecise.com.

Contacts

Investors:
LifeSci Advisors
John Mullaly
Email: jmullaly@lifesciadvisors.com

More News From ImmunoPrecise Antibodies Ltd.

MindWalk Announces Results of 2026 Annual General Meeting of Shareholders

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk" or the "Company") (NASDAQ: HYFT), a Bio-Native AI company, today announced the voting results of its 2026 Annual General Meeting of Shareholders held on November 17, 2026. A total of 18,619,753 common shares were represented by proxy at the meeting, representing 39.13% of the 47,574,512 common shares issued and outstanding as of the October 13, 2026 record date. Shareholders elected Dr. Jennifer L. Bath, Jon Lieber and Kim Remi...

MindWalk Closes US$30 Million Senior Unsecured Revolving Credit Facility

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced that it has entered into a definitive senior unsecured revolving credit agreement with Sanabil Cayman providing a committed revolving credit facility of up to US$30 million. The agreement, dated November 16, 2026, implements the binding term sheet announced on September 14, 2026. The facility is undrawn, MindWalk is under no obligation to borrow, and no fee accrues on th...

MindWalk Announces Agreement with Teva Australia to Support Defined Antibody-Discovery Workflows

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd (“Teva Australia”) to deploy ReefIQ™, MindWalk’s HYFT®-powered biological context layer with specified LensAI™ analytical capabilities, in support of a defined scope of antibody-discovery work. Teva Australia will use the AI capabilities to support discovery decisions based on generated predictions and ac...
Back to Newsroom